Skip to content

Evaluation of the Impact of an Expert Opinion During the Management of Patients With Severe Bleeding on Oral Anticoagulants.

Evaluation of the Impact of an Expert Opinion During the Management of Patients With Severe Bleeding on Oral Anticoagulants.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05928091
Acronym
BANET
Enrollment
1000
Registered
2023-07-03
Start date
2023-10-16
Completion date
2026-07-20
Last updated
2026-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhage

Keywords

anticoagulants, hemorrhage

Brief summary

The goal of this randomized clinical trial is to evaluate the impact of an expert opinion during the management of patients with severe bleeding on oral anticoagulants. The main question it aims to answer is : • Does an expert help of decision during the management of patients with severe bleeding is superior to classic management ? The centers will be randomized in one of the two groups : control group and interventional group. Patients will be followed for 3 months. At their inclusion they will be managed in conformity of the randomisation of their center. They will be followed at hour 0 + 6 , H0+24 and at the end of hospitalization. After 3 months, they will be called to assess the occurrence of thrombotic events ou hemorrhage complications. Researchers will compare the classic management versus the management with an expert opinion to see if the expert opinion is superior to classic management.

Interventions

OTHERPhone call to an expert team

Patients will be treated as the expert said when the investigator called him

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Centers will be randomized in two arms : * control group : each center will manage hemorrhage of participation as they usually did * interventional group : management of hemorrhage will be guided by the expert team

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Major patient treated with oral anticoagulants, admitted in an emergency department * For suspected major bleeding defined according to the criteria of the International Society of Thrombosis and Haemostasis * Able to give informed consent to participate in research or, in the event of an emergency, to take charge of a reference person * Affiliated to a Social Security scheme.

Exclusion criteria

* Pregnant or breastfeeding women * Patient under guardianship, curatorship or safeguard of justice * Administration within the last 24 hours of parenteral anticoagulant. * Refusal to participate

Design outcomes

Primary

MeasureTime frameDescription
Effectiveness of bleeding managementHour 24The effectiveness of the management of bleeding will be evaluated with a rate of compliance with the recommendations in the event of major bleeding under oral anticoagulants

Secondary

MeasureTime frameDescription
Mortality rate all causesInclusion + 3 monthsMortality rate all causes after 3 months
Hemostatic efficacy rateHour 24Hemostatic efficacy rate at 24 hours evaluated by an independent blinded evaluation committee
Specific mortality rate related to haemorrhageInclusion + 3 monthsSpecific mortality rate related to haemorrhage after 3 months
Rate of new bleedingInclusion + 3 monthsRate of new bleeding after 3 months
Thromboembolic eventsInclusion + 3 monthsMajor thrombosis including symptomatic proximal venous thrombosis, symptomatic or non-symptomatic pulmonary embolism, ischemic vascular accident, myocardial infarction, cerebral thrombophlebitis, mesenteric portal thrombosis at 3 months
Duration of hospital stayInclusion + 3 monthsDuration of hospital stay over the entire 3-month follow-up
Changes in haemostasis valuesHour 6Rate of correction of haemostasis disorders at 6 hours post-reversion defined by an INR of less than 1.5 for Vitamin K Antagnist and normalization of activated partial thromboplastin time, prothrombin time, anti-Xa activity according to local normal values.
Rate of avoided and avoidable reversionsHour 24Rate of avoided and avoidable reversions
Deadlines for implementing a reversionHour 24* Comparison of the time between the arrival of the patient in the emergency room and the implementation of the reversal * Comparison of the time between the patient's arrival in the emergency room and the performance of diagnostic imaging, particularly cerebral * Comparison of the time between the patient's arrival in the emergency room and the performance of a haemostatic procedure (interventional radiology, surgery, fibroscopy)

Countries

France

Contacts

PRINCIPAL_INVESTIGATORFares MOUSTAFA

University Hospital, Clermont-Ferrand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 1, 2026